Glenmark Life Sciences Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹65.37 billion
- Book Value:
- Revenue TTM:
- ₹21.61 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹11.76 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Glenmark Life Sciences Limited had its IPO on under the ticker symbol GLS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Glenmark Life Sciences Limited has a staff strength of 0 employees.
Shares of Glenmark Life Sciences Limited opened at ₹536.25 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹535 - ₹560.1, and closed at ₹552.95.
This is a +3.69% increase from the previous day's closing price.
A total volume of 421,776 shares were traded at the close of the day’s session.
In the last one week, shares of Glenmark Life Sciences Limited have increased by +5.36%.
Glenmark Life Sciences Limited's Key Ratios
Glenmark Life Sciences Limited has a market cap of ₹65.37 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Glenmark Life Sciences Limited’s revenue was ₹21.61 billion with a gross profit of ₹11.76 billion and an EBITDA of ₹6.42 billion. The EBITDA ratio measures Glenmark Life Sciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Glenmark Life Sciences Limited’s operating margin was 27.77% while its return on assets stood at 14.5% with a return of equity of 22.28%.
In Q1, Glenmark Life Sciences Limited’s quarterly earnings growth was a positive 48% while revenue growth was a positive 20.9%.
Glenmark Life Sciences Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹38.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Glenmark Life Sciences Limited’s profitability.
Glenmark Life Sciences Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Glenmark Life Sciences Limited stock pays annual dividends of ₹21 per share, indicating a yield of 7.81% and a payout ratio of 55.11%.
Balance sheet and cash flow metrics
- Total Assets
- ₹27.02 billion
- Total Liabilities
- ₹5.04 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Glenmark Life Sciences Limited ended 2023 with ₹27.02 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹27.02 billion while shareholder equity stood at ₹21.38 billion.
Glenmark Life Sciences Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹5.04 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹2.84 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Glenmark Life Sciences Limited’s total current assets stands at ₹18.50 billion while long-term investments were ₹0 and short-term investments were ₹964.78 million. Its net receivables were ₹8.07 billion compared to accounts payable of ₹3.97 billion and inventory worth ₹6.04 billion.
In 2023, Glenmark Life Sciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Glenmark Life Sciences Limited paid ₹0.55 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Glenmark Life Sciences Limited stock is currently trading at ₹552.95 per share. It touched a 52-week high of ₹560.05 and a 52-week low of ₹560.05. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹455.53 and 200-day moving average was ₹407.04 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 8284.9% of the company’s stock are held by insiders while 259.6% are held by institutions.
Frequently Asked Questions About Glenmark Life Sciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management. It also provides Atovaquone, Remogliflozin, Teneligliptin, Zonisamide, and Adapalene. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.